Results 231 to 240 of about 123,730 (305)

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Direct-to-Consumer Advertising of Prescription Drugs: What Can the Swiss Experience Tell Policy-Makers in the United States? [PDF]

Cureus
Umaru OT, Aremu TO.
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Public versus private healthcare systems in the OECD area- a broad evaluation of performance. [PDF]

Eur J Health Econ
Molander P.
europepmc   +1 more source

Access and Reimbursement for Artificial Intelligence in Radiology: A Central Asian Perspective. [PDF]

Korean J Radiol
Dautov T, Darbaeva A, Aimagambetova Z, Polushkin V.   +3 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

A realist evaluation of the development, implementation and outcomes of the first public ART Centre in Morocco. [PDF]

PLOS Glob Public Health
Benbella A, Zaidouni A, Elomrani S, Mburu G, Hardizi H, Yahyane A, Hachri H, Gholbzouri K, Kiarie J, Bezad R.   +9 more
europepmc   +1 more source

A Prelude to the Welfare State: The Origins of Workers' Compensation [PDF]

Price V. Fishback, Shawn Everett Kantor
core  

How to apply The access to Public Information Act [PDF]

, 2001
-
core  

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source